Drug profile

The FDA adverse-event record for N-Butyryl Glucosamine

13 FDA reports name N-Butyryl Glucosamine, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2270 of 2,679
by report volume (all drugs)
13
adverse-event reports
15.4%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, N-Butyryl Glucosamine ranks #2210 of 2679 by total reports (13). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2210
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. N-Butyryl Glucosamine has 13 reports now versus 12 in that prior snapshot: 1 more (8.3%).

Report change
+1
Death-coded reports
+0
Death-coded share
−1.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to N-Butyryl Glucosamine changes

Signature read: 13 reports place N-Butyryl Glucosamine in the lower third of FDA AER volume (#2270 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
2
Deaths Reported
15.4%
Death-coded share of reports

Active Ingredients

N-Butyryl Glucosamine

Administration Routes

UnknownOralSubcutaneous

Species Affected

Dog 13

Most Affected Breeds

Retriever - Labrador 3
Boxer (German Boxer) 2
Doberman Pinscher 2
Mountain Dog - Bernese 1
Beagle 1
Dog (other) 1
Dachshund - Standard Long-haired 1
Hound - Great Anglo-French (unspecified) 1
Dog (unknown) 1

Most Reported Reactions

Death by euthanasia 2
Not eating 2
Vomiting 2
Uncomfortable 1
Restlessness 1
Partial anorexia 1
Behavioural disorder NOS 1
Bruising 1
Weight loss 1
General illness 1
Head tremor 1
Renal failure 1

Outcome Breakdown

Outcome Unknown
6 (46.2%)
Ongoing
3 (23.1%)
Euthanized
2 (15.4%)
Recovered/Normal
2 (15.4%)

N-Butyryl Glucosamine: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for N-Butyryl Glucosamine (#2270 of 2,679 by report volume); death-coded 15.4%. PlainBreed drug row · report volume stamp 13 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →